Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

SB3 is a biosimilar of trastuzumab that has been approved for use in the treatment of human epidermal growth factor 2-positive breast cancer and human epidermal growth factor 2-positive gastric cancer. Antibody-dependent cellular cytotoxicity is one of several critical quality attributes of trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lüftner, Diana, Lyman, Gary H., Gonçalves, João, Pivot, Xavier, Seo, Minji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560928/
https://www.ncbi.nlm.nih.gov/pubmed/32748046
http://dx.doi.org/10.1007/s11523-020-00742-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560928/
https://www.ncbi.nlm.nih.gov/pubmed/32748046
http://dx.doi.org/10.1007/s11523-020-00742-w

Ejemplares similares